The Research and Development Society

Asia-Pacific Technology Network event in association with Olswang, the London Biotechnology Network and the R&D Society
Wednesday 7 May 2008, 5.15pm
Olswang, 90 High Holborn, London, WC1V 6XX - map

Spurred on by global ambitions of its top players, formidable core competencies and an evolving global marketplace, the Indian pharmaceutical industry is perhaps at inflection point towards a phase of high value growth with increasing international revenues and the emergence of innovative business models. Dr Brian Tempest - former Chief Mentor and Executive Vice Chairman of Ranbaxy Laboratories is particularly well placed to draw on his experiences both at Ranbaxy - one of the world's largest generic pharmaceutical companies and within global pharmaceutical leadership roles over 37 years, to discuss what future leading Indian pharmaceutical companies will look like, and what opportunities this presents for UK R&D.

Professor Barry Furr, former Chief Scientific Officer at Astra Zeneca, well versed with pharmaceutical R&D across the world including notably Astra Zeneca's Tuberculosis Research Center in Bangalore will moderate the discussion raising pertinent questions. This event will be a unique opportunity to learn the views of two experienced industry veterans about a group of companies that could well shake up the global industry.

Biographies:

Barry Furr, Former Chief Scientist AstraZeneca (Chair)

Barry Furr is a reproductive biologist and endocrinologist by training who worked for over 33 years at AstraZeneca and its associate companies. He held a range of research management positions, retiring in 2005 as Chief Scientist. He worked on the antioestrogenic breast cancer drug, tamoxifen, and both Zoladex and Casodex for prostate cancer were discovered in his laboratory. He is a Fellow of the Academy of Medical Sciences and Institute of Biology, and has an honorary chair at the University of Manchester. He is a William Pitt Fellow at Pembroke College, Cambridge and a Trustee of the Breast Cancer Campaign and CRUK. He has been Chairman of the Industry Forum of the Academy of Medical Sciences and of the Society of Endocrinology and a council member of the Biosciences Federation. He was awarded an OBE in 2000 for his contribution to cancer research. He is now a consultant for a number of important companies, including AstraZeneca, Abingworth, Modern Bioscience and Astex, and is a non-executive Director of Genus.

Dr Brian W Tempest, Chief Mentor & Executive Vice Chairman of the Board, Ranbaxy Laboratories, New Delhi, India (Speaker)

Dr. Brian Tempest has worked in the pharma industry for the last 36 years. During this time he has worked for several pharma majors, including Glaxo & Searle, around the world and joined Ranbaxy 12 years ago. During this period Ranbaxy has transformed from a small company focused on the India domestic market, to a top 10 global generic company. Dr. Tempest lives in New Delhi, India and has been President, Managing Director & Chief Executive Officer and is presently the Chief Mentor & Executive Vice Chairman of the Board. Dr. Tempest retired from Ranbaxy in 2007. Dr. Tempest is one of a few westerners to hold a leadership position in an Indian blue chip MNC, and has a unusual insight into India.Dr Tempest is also an Honorary Professor of the Management School at Lancaster University, UK, and he sits on the Editorial Board of the Journal of Generic Medicines.